

# JosÃ©-Vicente Torregrosa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/76706/publications.pdf>

Version: 2024-02-01

48  
papers

777  
citations

567281

15  
h-index

552781

26  
g-index

53  
all docs

53  
docs citations

53  
times ranked

930  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cardiovascular calcifications in kidney transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 2063-2071.	0.7	9
2	Antiphospholipase A2 receptor antibody-positive membranous nephropathy in the kidney donor: Lessons from a serendipitous transplantation. <i>American Journal of Transplantation</i> , 2022, 22, 299-303.	4.7	3
3	La "Semana del Sforo": implicaci3n de la nefrologa espa±ola en el control de los valores plasmáticos de f3sforo. <i>Nefrologia</i> , 2022, , .	0.4	0
4	FC 110: Survival Benefit of Preemptive Simultaneous Pancreas-Kidney Transplantation. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
5	The impact of functional delayed graft function in the modern era of kidney transplantation " A retrospective study. <i>Transplant International</i> , 2021, 34, 175-184.	1.6	9
6	Taking care of kidney transplant recipients during the COVID-19 pandemic: Experience from a medicalized hotel. <i>Clinical Transplantation</i> , 2021, 35, e14132.	1.6	5
7	Adoption of a novel smart mobile health application technology to track chronic immunosuppression adherence in solid organ transplantation: Results of a prospective, observational, multicentre, pilot study. <i>Clinical Transplantation</i> , 2021, 35, e14278.	1.6	7
8	Bone Mineral Disease After Kidney Transplantation. <i>Calcified Tissue International</i> , 2021, 108, 551-560.	3.1	16
9	Combination of calcineurin and mTOR inhibitors in kidney transplantation: a propensity score analysis based on current clinical practice. <i>Journal of Nephrology</i> , 2020, 33, 601-610.	2.0	13
10	Use of De Novo mTOR Inhibitors in Hypersensitized Kidney Transplant Recipients: Experience From Clinical Practice. <i>Transplantation</i> , 2020, 104, 1686-1694.	1.0	8
11	P1748 PARATHYROIDECTOMY REMAINS EFFECTIVE FOR TREATING TERTIARY HYPERPARATHYROIDISM: LONG-TERM RESULTS OF A RANDOMIZED STUDY. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
12	P1840 EVOLUTION OF FACTORS ASSOCIATED WITH THE DEVELOPMENT OF CALCIPHYLAXIS AFTER KIDNEY TRANSPLANTATION. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
13	Panel Discussion: Some Aspects of the Management of Patients with X-Linked Hypophosphataemic Rickets. <i>Advances in Therapy</i> , 2020, 37, 121-126.	2.9	2
14	Improvement in wound healing, pain, and quality of life after 12 weeks of SNF472 treatment: a phase 2 open-label study of patients with calciphylaxis. <i>Journal of Nephrology</i> , 2019, 32, 811-821.	2.0	31
15	SP773 Evaluating adherence to immunosuppressive drugs through Trackyourmed® an innovative QR code-scanner app in renal transplantation: Preliminary results from I-COM trial. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.7	0
16	Osteoporosis, densidad mineral 3sea y complejo CKD-MBD (I): consideraciones diagn3sticas. <i>Nefrologia</i> , 2018, 38, 476-490.	0.4	33
17	Aspectos actuales de la enfermedad de Fabry. <i>Medicina Clínica</i> , 2018, 151, 196-197.	0.6	0
18	Fabry Nephropathy: An Evidence-Based Narrative Review. <i>Kidney and Blood Pressure Research</i> , 2018, 43, 406-421.	2.0	35

#	ARTICLE	IF	CITATIONS
19	Calcifilaxis en pacientes con enfermedad renal crÃ³nica: una enfermedad todavÃa desconcertante y potencialmente mortal. Nefrologia, 2018, 38, 579-586.	0.4	16
20	Higher Proportion of Non-1-84 PTH Fragments in Peritoneal Dialysis Patients Compared to Hemodialysis Patients Using Solutions Containing 1.75 mmol/l Calcium. Frontiers in Physiology, 2018, 9, 1643.	2.8	3
21	Calciphylaxis in patients with chronic kidney disease: A disease which is still bewildering and potentially fatal. Nefrologia, 2018, 38, 579-586.	0.4	12
22	FOO20A PHASE 2 OPEN-LABEL SINGLE-ARM STUDY TO ASSESS THE EFFECT OF SNF472 ON WOUND HEALING IN CALCIPHYLAXIS (CALCIFIC UREMIC ARTERIOLOPATHY) PATIENTS. Nephrology Dialysis Transplantation, 2018, 33, i9-i9.	0.7	2
23	Interacciones farmacolÃ³gicas de los captores del fÃ³sforo. Nefrologia, 2018, 38, 573-578.	0.4	16
24	An mTOR-inhibitor-based protocol and calcineurin inhibitor (CNI)-free treatment in kidney transplant recipients from donors after cardiac death: good renal function, but high incidence of conversion to CNI. Transplant International, 2016, 29, 362-368.	1.6	9
25	Is there a role for PET/CT in the evaluation of primary and secondary hyperparathyroidism?. Nuclear Medicine Communications, 2016, 37, 1-2.	1.1	7
26	Comparison of two different vitamin D supplementation regimens with oral calcifediol in kidney transplant patients. Journal of Nephrology, 2016, 29, 703-709.	2.0	9
27	Monthly ibandronate versus weekly risedronate treatment for low bone mineral density in stable renal transplant patients. Nuclear Medicine Communications, 2015, 36, 815-818.	1.1	10
28	DXA Variations and Fractures After Simultaneous Pancreas-Renal Transplantation. Clinical Nuclear Medicine, 2015, 40, e232-e235.	1.3	2
29	Blueprint for a European calciphylaxis registry initiative: the European Calciphylaxis Network (EuCalNet). CKJ: Clinical Kidney Journal, 2015, 8, 567-571.	2.9	12
30	Set point of calcium in severe secondary hyperparathyroidism is altered and does not change after successful kidney transplantation. Endocrine, 2015, 48, 709-711.	2.3	5
31	Cinacalcet for hypercalcaemic secondary hyperparathyroidism after renal transplantation: a multicentre, retrospective, 3-Ã©year study. Nephrology, 2014, 19, 84-93.	1.6	19
32	What is the role of preoperative scintigraphic imaging and the intraoperative gamma probe in secondary hyperparathyroidism?. Nuclear Medicine Communications, 2014, 35, 443-445.	1.1	8
33	REFOS study: efficacy and safety of lanthanum carbonate in clinical practice in Spain. Nefrologia, 2014, 34, 360-8.	0.4	2
34	Advantages of Pinhole Collimator Double-Phase Scintigraphy With 99mTc-MIBI in Secondary Hyperparathyroidism. Clinical Nuclear Medicine, 2013, 38, 878-881.	1.3	6
35	Dramatic increase in parathyroid hormone and hypocalcaemia after denosumab in a kidney transplanted patient. CKJ: Clinical Kidney Journal, 2013, 6, 122-122.	2.9	17
36	Management of hypercalcemia after renal transplantation. Nefrologia, 2013, 33, 751-7.	0.4	19

#	ARTICLE	IF	CITATIONS
37	Clinical management of calcific uremic arteriolopathy before and after therapeutic inclusion of bisphosphonates. <i>Clinical Nephrology</i> , 2013, 83, 231-4.	0.7	17
38	Spanish Society of Nephrology recommendations for controlling mineral and bone disorder in chronic kidney disease patients (S.E.N.-M.B.D.). <i>Nefrologia</i> , 2011, 31 Suppl 1, 3-32.	0.4	37
39	Open-Label Trial: Effect of Weekly Risedronate Immediately After Transplantation in Kidney Recipients. <i>Transplantation</i> , 2010, 89, 1476-1481.	1.0	44
40	Arteriovenous Fistula Affects Bone Mineral Density Measurements in End-Stage Renal Failure Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1494-1499.	4.5	14
41	Dual-phase 99mTc-MIBI scintigraphy to assess calcimimetic effect in patients on haemodialysis with secondary hyperparathyroidism. <i>Nuclear Medicine Communications</i> , 2009, 30, 890-894.	1.1	15
42	Effect of Cinacalcet on Hypercalcemia and Bone Mineral Density in Renal Transplanted Patients With Secondary Hyperparathyroidism. <i>Transplantation</i> , 2008, 86, 413-417.	1.0	87
43	Role of pre-operative imaging using 99mTc-MIBI and neck ultrasound in patients with secondary hyperparathyroidism who are candidates for subtotal parathyroidectomy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 467-473.	6.4	42
44	Effect of hemodialysis and renal failure on serum biochemical markers of bone turnover. <i>Journal of Bone and Mineral Metabolism</i> , 2004, 22, 254-259.	2.7	32
45	Usefulness of pamidronate in severe secondary hyperparathyroidism in patients undergoing hemodialysis. <i>Kidney International</i> , 2003, 63, S88-S90.	5.2	33
46	Loss of heterozygosity in renal and hepatic epithelial cystic cells from ADPKD1 patients. <i>European Journal of Human Genetics</i> , 2000, 8, 487-492.	2.8	31
47	99mTc-sestamibi Scintigraphy and Cell Cycle in Parathyroid Glands of Secondary Hyperparathyroidism. <i>World Journal of Surgery</i> , 2000, 24, 1386-1390.	1.6	65
48	Vitamin D Receptor Gene Polymorphisms and Bone Mineral Density in Patients on Hemodialysis. <i>Nephron</i> , 2000, 84, 381-382.	1.8	2